AREC: Cash runway to Q2 2027 enables phase II AT278 trial and oral peptide delivery progress
Revenue and cash position improved, supported by a $11M non-dilutive financing and reduced expenses. AT278 insulin and oral peptide delivery platforms advance, with phase II…
TR
By Tom Reyes · Markets Editor
Nov 5 05:18 ETSource: TradingView
From the source
Read at tradingview.comAREC: Cash runway to Q2 2027 enables phase II AT278 trial and oral peptide delivery progress
Revenue and cash position improved, supported by a $11M non-dilutive financing and reduced expenses. AT278 insulin and oral peptide delivery platforms advance, with phase II trials and key data expected in 2026. Strategic partnerships and a strong cash runway support growth.
